Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Witzig, Thomas E., Tang, Hui, Micallef, Ivana N. M., Ansell, Stephen M., Link, Brian K., Inwards, David J., Porrata, Luis F., Johnston, Patrick B., Colgan, Joseph P., Markovic, Svetomir N., Nowakowski, Grzegorz S., Thompson, Carrie A., Allmer, Cristine, Maurer, Matthew J., Gupta, Mamta, Weiner, George, Hohl, Ray, Kurtin, Paul J., Ding, Husheng, Loegering, David, Schneider, Paula, Peterson, Kevin, Habermann, Thomas M., Kaufmann, Scott H.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2011
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208296/
https://ncbi.nlm.nih.gov/pubmed/21725056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-334904
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items